Abbreviated dose rituximab for immune-mediated hematological disorders

American Journal of Hematology

Volumn 83, Issue 7, 2008, Pages 554-557

  Fairweather, Helen ^a   Tuckfield, Annabel ^a   Grigg, Andrew ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BLOOD CLOTTING FACTOR 8 INHIBITOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; PREDNISOLONE; RITUXIMAB; STEROID; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; BLOOD CLOTTING DISORDER; CLINICAL ARTICLE; DISEASE DURATION; DRUG DOSE REGIMEN; DRUG RESPONSE; FEMALE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INJECTION SITE REACTION; MALE; NEUTROPENIA; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT DISEASE; REFRACTORY ANEMIA; REMISSION; SINGLE DRUG DOSE; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; B-LYMPHOCYTES; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR VIII; FEMALE; HEMATOLOGIC DISEASES; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE COUNT; MALE; MIDDLE AGED;

EID: 45749144416     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21143     Document Type: Article

References (22)

1. Stasi R, Provan D. Management of immune thrombocytopenic purpura in adults. Mayo Clin Proc 2004;79:504-522.
2. Shumak KH, Rock GA, Nair RC. Late relapses in patients successfully treated for thrombotic thrombocytopenic purpura. Canadian Apheresis Group. Ann Int Med 1995;122:569-572.
3. Portielje JEA, Westendorp RGJ, Kluin-Nelemans HC, Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001;97: 2549-2554.
4. Pizzuto J, Ambriz R. Therapeutic experience in 934 adults with idiopathic thrombocytopenic purpura: Multicentric trial of the Cooperative Latin American Group on hemostasis and thrombosis. Blood 1984;64:1179-1183.
5. Alfred SL, Hunt BJ, Rose P, Machin SJ. Guidelines on the diagnosis and management of thrombotic microangiopathic haemolytic anaemias. Br Haematol 2003;120:556-573.
6. Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001;988:952-957.
7. Reddy PS, Deauna-Limayo D, Cook JD, et al. Rituximab in the treatment of relapsed thrombotic thrombocytopenic purpura. Ann Hematol 2005;84:232-235.
8. Shanafelt TD, Madueme HL, Wolf RC, Tefferi A. Rituximab for immune cytopenias in adults: Idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia and Evans syndrome. Mayo Clin Proc 2003;78:1340-1346.
9. Aggarwal A, Grewal R, Green RJ, et al. Rituximab for autoimmune haemophilia: A proposed treatment algorithm. Haemophilia 2005;11:13-19.
10. Leandro MJ, Cooper N, Cambridge G, et al. Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy. Rheumatology 2007;46:29-36.
11. Maloney DG, Grillo-López AJ, White CA, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkins lymphoma. Blood 1997;90:2188-2195.
12. Edwards JCW, Szczepański L, Szechiński J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-1581.
13. Maloney DG, Grillo-López AJ, Bodkin DJ, et al. IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkins lymphoma. J Clin Oncol 1997;15:3266-3274.
14. Maloney DG, Liles TM, Czerwinski DK, et al. Phase I trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-2B8) in patients with recurrent B-cell lymphoma. Blood 1994;84:2457-2466.
15. Vieira CA, Agarwal A, Book BK, et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation, Part 1: Safety, pharmacodynamics, and pharmacokinetics. Transplantation 2004;77:542-548.
16. Cooper N, Stasi R, Cunningham-Rundles S, et al. The efficacy and safety of B-cell depletion with ani-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol 2004;125:232-239.
17. Peñalver FJ, Jiménez-Yuste J, Almagro M, et al. Rituximab in the management of chronic immune thrombocytopenic purpura: An effective and safe therapeutic alternative in refractory patients. Ann Hematol 2006;85:400-406.
18. Sallah S, Husain A, Wan JY, Ngyuen P. Rituximab in patients with refractory thrombotic thrombocytopenic purpura. J Thromb Haemost 2004;2:834-836.
19. Wiestner A, Cho HF, Asch A, et al. Rituximab in the treatment of acquired factor VIII inhibitors. Blood 2002;100:3426-3428.
20. Taube T, Schmid H, Reinhard H, et al. Effect of a single dose of rituximab in chronic immune thrombocytopenic purpura in childhood. Haematologica 2005;90:281-283.
21. Arnold DM, Dentali F, Crowther MA, et al. Systematic review: Efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Int Med 2007;146:25-33
22. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphism independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003;21:3940-3947.